

Aus der Universitätsklinik für Neurologie, Inselspital Bern

Direktor: Prof. Dr. med. C. Bassetti

Arbeit unter der Leitung von PD. Dr. med. R. Hoepner und Dr. med. L. Diem

Efficacy and safety of ocrelizumab in patients with relapsing multiple sclerosis: real-world experience of two Swiss Multiple Sclerosis centers

Inaugural-Dissertation zur Erlangung der Doktorwürde der Humanmedizin der Medizinischen Fakultät der Universität Bern

vorgelegt von

Arkady Matveevich Ovchinnikov

aus Bulgarien

publiziert in Journal Multiple Sclerosis and Related Disorders (Elsevier)



Dieses Werk ist lizenziert unter einer Creative Commons Namensnennung 4.0 International Lizenz <https://creativecommons.org/licenses/by/4.0/deed.de>

**Von der Medizinischen Fakultät der Universität Bern auf Antrag der
Dissertationskommission als Dissertation genehmigt.**

Promotionsdatum:

Der Dekan der Medizinischen Fakultät:

1 **Efficacy and safety of ocrelizumab in patients with relapsing multiple sclerosis: real-world**
2 **experience of two Swiss Multiple Sclerosis centers**

3

4 Diem L^{1,2}, Ovchinnikov A³, Friedli C¹, Hammer H¹, Kamber N¹, Chan A¹, Salmen A¹, Findling O^{3*},
5 Hoepner R^{1*}

6 1. Department of Neurology, Inselspital, Bern University Hospital and University of Bern,
7 Freiburgstrasse, Bern, Switzerland.

8 2. Neurocenter, Lucerne Cantonal Hospital, 6000 Lucerne, Switzerland

9 3. Department of Neurology, Cantonal Hospital Aarau (Kantonsspital Aarau), Tellstrasse,
10 Aarau, Switzerland

11

12 * These authors contributed equally to this work.

13

14

15

16

17 Corresponding author: Lara Diem, Department of Neurology, Inselspital, Bern University Hospital and
18 University of Bern, Freiburgstrasse, Bern, Switzerland E-Mail: diem.lara@gmail.com

19

20 Character count incl., spaces of the title: 6241

21 Word count of the main text: 2900

22 Number of tables/figures: 1 and 3 respectively

23 Number of references: 30

24 Number of supplement tables/figures: 2

25

26 Key Words: Ocrelizumab, multiple sclerosis, Relapsing multiple sclerosis, immunotherapy

27

28 Running title: real-world data, ocrelizumab

29

30

31

32

33

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27

Conflict of interest statement

Diem L received travel grants from Merck, Biogen, Roche and Bayer Schweiz. She also received speaker's honoraria from Biogen, Novartis, Lundbeck and Merck

Ovchinnikov A declared to have no conflict of interest

Hammer H received research support and travel grants from Biogen, Merck, Roche & BMS

Friedli C received travel grants from Biogen and Sanofi Genzyme and speaker honoraria from Biogen and Merck, unrelated to this work. He reports no conflicts of interest related to this manuscript.

Kamber N received travel and/or speaker honoraria, served on advisory boards for Alexion, Biogen, Merck, Sanofi Genzyme and Roche, and received research support from Biogen.

Chan A received speakers'/board honoraria from Actelion (Janssen/J&J), Almirall, Bayer, Biogen, Celgene (BMS), Genzyme, Merck KGaA (Darmstadt, Germany), Novartis, Roche, and Teva, all for hospital research funds. He received research support from Biogen, Genzyme, UCB, the European Union, and the Swiss National Foundation. He serves as associate editor of the European Journal of Neurology, on the editorial board for Clinical and Translational Neuroscience and as topic editor for the Journal of International Medical Research.

Salmen A received speaker honoraria and/or travel compensation for activities with Almirall Hermal GmbH, Biogen, Merck, Novartis, Roche and Sanofi Genzyme, and research support of Baasch Medicus Foundation and the Swiss MS society, not related to this work.

Findling O received travel support or support for education from Merck and Bristol Meyers Squibb.

Hoepner R received speaker/advisor honorary from Merck, Novartis, Roche, Biogen, Alexion, Sanofi, Bristol-Myers Squibb, and Almirall. In the last five years, he received research support from Roche, Merck, Sanofi, Biogen, and Bristol-Myers Squibb. He also received research grants from the Swiss MS Society. All are not related to that work.

1 **Abstract:**

2 **Background:**

3 Ocrelizumab (OCR) is a humanized monoclonal antibody directed against CD-20 positive lymphocytes,
4 mainly B-lymphocytes. OCR is approved for treatment of primary progressive (PPMS) and relapsing
5 multiple sclerosis (RMS). This study aims to provide real-world safety and efficacy data of people with
6 RMS treated with OCR in two Swiss Multiple Sclerosis (MS) centers.

7 **Methods:**

8 We have conducted a retrospective data analysis using the patient cohorts from the Cantonal Hospital
9 Aarau and Bern University Hospital (RMS: n=235). Statistical analyses were performed with Mann–
10 Whitney U-Test, Chi-squared test and Spearman-Rho-Correlation. Adjustment for multiple testing was
11 performed by Bonferroni procedure.

12 **Results:**

13 After initiation of OCR, there was a decrease in disease activity in RMS patients. In our study, 152/190
14 (80.0%) RMS patients fulfilled the criteria for NEDA-3 12 months and 88/104 (84.6%) showed NEDA-3
15 24 months after OCR initiation. The most frequent adverse events (AEs) in our study were infections,
16 taking place in 78/235 (33.2%) RMS patients. COVID-19 was the most common infection, followed by
17 urinary infections and other respiratory infections and infectious adverse events occurred significantly
18 more frequent in patients with reduced IgG serum concentration.

19 **Conclusions:**

20 Our real-world study showed OCR being associated with low rates of any type of MS disease activity
21 as indicated by NEDA-3. The adverse event profile is comparable to the known events especially
22 infections and an association between infections and reduced IgG serum concentration was found.

23

24

25

26

27

28

29

30

31

32

33

34

1 **Introduction**

2 B-lymphocytes, which express CD-20 antigen on the cell surface, are supposed to be actively involved
3 in the chronic inflammation present during multiple sclerosis (MS) disease [1]. Immunotherapy with
4 Ocrelizumab (OCR), which is a humanized anti-CD-20 monoclonal antibody, was approved by the US
5 Food and Drug Administration (FDA) [2] and by the Swissmedic in 2017 [3] and in 2018 by European
6 Medicines Agency (EMA) [4] for treatment of patients with relapsing (RMS) and primary progressive
7 forms of multiple sclerosis (PPMS) [5, 6].

8 In the OPERA I and II trials in patients with RRMS, OCR significantly reduced ARR vs. interferon β -1a
9 by 46% and the number of gadolinium-enhancing lesions by 94%. [5] In these studies, the most common
10 adverse events of OCR were mild to moderate infusion-related reactions and infections [5, 7].

11 Randomized controlled trials (RCTs) are essential for demonstrating efficacy and safety prior market
12 approval. However, their power is limited partly because the results may not be broadly generalizable,
13 as the inclusion of patients with different comorbidities, previous treatments, or elderly patients may be
14 restricted. Studies under real-world conditions may therefore complement RCTs. In the last three years,
15 the number of real-world data studies on OCR has increased (currently about 8 studies, supplementary
16 table 1) but is still limited [8-18]

17 The aim of our real-world study is to provide information about treatment efficiency for RMS patients,
18 considering their previous treatment and comorbidities in two Swiss MS centers.

19 **Methods**

20 **Patients and Study Design**

21 We have conducted a retrospective study in two Swiss MS centers (Cantonal Hospital Aarau and
22 University Hospital in Bern), collecting the information of in total 235 RMS patients (figure 1). Eligible
23 patients were identified using the following search terms "MS and Ocrelizumab or Ocrevus" in the
24 centers Aarau and Bern to search local clinical information systems within the following time frames:
25 January 2016 till January 2022. In these 2 centers, the patients were seen 6 and 12 months after the
26 start of ocrelizumab, subsequently every 6 months. During the consultation, relapses were evaluated
27 and EDSS and laboratory chemical tests were performed. Patients underwent brain MRI (using 1.5 T or
28 3 T scanners) every year after start of ocrelizumab. In some cases, control MRI at 4 to 6 months (re-
29 baseline MRI) was performed on an individual basis. MRI before ocrelizumab start was performed on
30 an individual basis. Baseline follow-up information's were collected from medical records: age, sex, first
31 manifestation and time point of MS diagnosis, type of multiple sclerosis, disease modifying therapy
32 (DMT) before starting with OCR (supplementary table 2), Expanded Disability Status Scale (EDSS)
33 score at OCR initiation and 24, 12 months (+/- 8 weeks) before and after start of OCR treatment,
34 information about relapses before (12 and 24 months) and under OCR therapy, magnetic resonance
35 imaging (MRI) findings at 24, 12 (+/- 8 weeks) months before and after the beginning of the OCR
36 treatment, lymphocyte and neutrophil count, liver parameters, serum immunoglobulin G (IgG) under the
37 therapy, adverse events including infusion related reactions (IRR).

38

1 Clinical and MRI outcomes

2 MS diagnosis was in accordance with the currently valid 2017 McDonald criteria [19]. As a clinical MS
3 relapse, we have considered a new onset of the neurological symptoms with a minimal duration of at
4 least 24h, considering the absence of infection/fever, Uhthoff-phenomenon [20].

5 Disease progression was defined as an increase of the EDSS Score by 1 point if the baseline EDSS
6 was 0 to 5.5 and by 0.5 points if the baseline EDSS score was ≥ 6.0 compared to the last clinical
7 assessment [21]. EDSS improvement was defined as a decrease of the EDSS Score by 1 point if the
8 baseline EDSS was 0 to 5.5 and by 0.5 points if the baseline EDSS score was ≥ 6.0 compared to the
9 last clinical assessment.

10 Annualized relapse rate (ARR) was defined as the number of relapses with onset occurring during a
11 specific period, adjusted to a one-year period. Radiological activity in MRI scans was classified by the
12 presence of T1 -Gadolinium enhancing lesions (GELs), new or enlarging T2 lesions compared to the
13 last scan. No evidence of disease activity (NEDA-3) was considered as the main criteria for clinical
14 efficacy assessment and consisted of the following information: presence of MS relapses, and/or
15 radiological evidence of disease activity (and/or disability progression [22]). Hypogammaglobulinemia for
16 IgG was defined as a serum IgG concentration below $< 6.0\text{g/l}$ (17). The overall IgG decrease was
17 calculated as follows: (IgG value just before OCR therapy initiation - last IgG value under OCR
18 therapy)/time in years. Agranulocytosis was defined as absolute neutrophil count below < 500 cells per
19 microliter (μl) [23] and transaminase increase as Aspartate transaminase and/or Alanine transaminase
20 > 35 U/l [23]. Adverse events classified using the Common Terminology Criteria for Adverse Events
21 (CTCAE) [24].

22 Statistics

23 Quantitative variables are described using the mean and 95% confidence interval (95%CI) or median
24 and interquartile range (IQR) and compared with Wilcoxon Test. Qualitative variables are presented as
25 absolute and relative frequencies and were compared with Mc-Nemar-Test. Adjustment for multiple
26 testing was performed by Bonferroni procedure regarding each domain independently. The statistical
27 package used was the IBM SPSS Statistics version 28.

28 Ethics

29 The ethics committee of North-West and Central Switzerland approved the study (Project-ID: AG 2016-
30 02233 amendment 01 03.05.2021; BE 2017-01369).

31

32

1 Results

2 Baseline characteristics

3 We conducted a retrospective observational study between April 2016 and January 2022, including 235
4 RMS patients in the two Swiss MS centers (figure 1). The majority of patients were female (157/235
5 (66.8)) and the mean age was 40.6 years (95% confidence interval (95%CI) (38.8–41.9); n = 235).
6 Median EDSS before OCR treatment was 2.0 (interquartile range (IQR) ± 1.5) n = 235). Mean disease
7 duration was 9.3 years (95%CI (8.4-10.2); n = 235).

8 The number of naïve, defined as without any prior immunotherapy, RMS patients was 75/235 (31.9%).
9 RMS patients switched mainly from (highly) active therapies (95/235), while from mild/moderate
10 therapies were by (65/235). In our cohort there were 7 patients on rituximab. In these patients, side
11 effects were the reason for switching to ocrelizumab. Prior to initiation of therapy with OCR, 49/75 of
12 naïve patients and 66/160 of pretreated patients had relapses 12 months before start with OCR,
13 respectively. Median EDSS in both groups was 2.0 (naïve median (\pm IQR) 2.0 (± 1.5), n=75; pretreated
14 mean (\pm IQR) 2.0 (± 1.6), n=160). MRI data were available in 65 of the naïve patients and of these 41/65
15 showed radiological activity. Of the 148 pretreated patients in whom MRI data were available, 56/148
16 showed MRI activity.

17 Treatment Efficacy

18 Data on relapses, EDSS progression, and MRI activity 12 month after OCR start were available in 190
19 patients. After initiation of OCR, there was a decrease in disease activity in RMS patients after 12
20 months. The number of patients with relapse (before OCR: 60/190 (31.6%) vs. after OCR: 5/190 (2.6%),
21 p-value <0.001) and the ARR (before OCR: 0.4 (0.3-0.4), n=190 vs. after OCR 0.03 (0.003-0.05), n=190,
22 p-value <0.001) dropped significantly by 92.5% after initiation of OCR. Relapses under ocrelizumab
23 occurred on a mean of 1.1 years (95%CI 0.20-3.08, n=11) after the start of therapy. In addition, there
24 was a significant decrease in MRI disease activity (new T2 lesions and/or Gd-enhancement lesions
25 before OCR: 88/190 (46.3%) vs. after OCR: 22/190 (11.6%); p-value <0.001). The median EDSS
26 remained stable in the majority of patients (stable EDSS: 165/190 (86.8%); EDSS improvement: 9/19
27 (4.7%), EDSS decline: 16/190 (8.4%), table 3). In our study, 152/190 (80.0%) RMS patients fulfilled the
28 criteria for NEDA-3 12 months after beginning of OCR, while 38/190 (20.0%) showed evidence of
29 disease activity (EDA): mainly presenting with MRI activity alone (19/38 radiological activity without
30 relapse or EDSS progression; 11/38 only progression; 2/38 radiological activity with progression; 4/38
31 only relapse; 1/38 relapse with progression and 1/38 with all 3 activity criteria, table 1). Considering the
32 new term “Progression Independent of Relapse Activity “(PIRA) 13/38 of the patients with disease
33 activity met the criteria for PIRA after 12 months. NEDA-3 status at 12 months was not associated with
34 disease duration (p=0.115) or pre-treatment status (p=0.172)

35 There were complete data sets on clinical and paraclinical course of 104/190 patients even after 24
36 months. In this cohort with a 24 months follow up the disease course was stable with low radiological
37 activity (4/104, 3.8%) and low ARR (mean (95%CI) 0.04 (0.001-0.08), n=104). At 24 months, 88/104
38 (84.6%) of the RMS patients fulfilled the criteria for NEDA-3 with EDSS progression being the main

1 reason for EDA in 9/104 patients (table 1). This is reflected in a small but significant EDSS increase in
2 the whole cohort (before OCR 2.0 (± 2.0), n=104 vs. after OCR 2.5 (± 1.5), n=104, p=0.003, table 3). In
3 number EDSS progression was present in 9/104 patients whereas a stable EDSS was seen in 89/104
4 and EDSS improvement only in 6/104. After 24 months, 9/16 patients with disease activity met the
5 criteria of PIRA. NEDA-3 status at 24 months was not associated with disease duration (p=0.119) or
6 pre-treatment status (p=0.353)

7 Adverse Events (AEs)

8 No fatal AE occurred. Severe AEs were COVID-19 with hospitalization (9/235, 3.8%), agranulocytosis
9 (2/235, 0.9%) and cytokine release syndrome CTCAE grade III (1/235, 0.4%) for which the patient was
10 also hospitalized (1/235, 0.4%).

11 Internationally recognized premedication protocols were used prior OCR infusions (1g Paracetamol p.o.,
12 5mg Levocetirizin p.o. and 100 – 125 mg Methylprednisolone i.v.) [25]. One patient had a cytokine
13 release syndrome Grade III with fever, exanthema, nausea and hypotension and need hospitalization
14 with steroids, nonsteroidal anti-inflammatory drug and volume substitution.

15 The most frequently documented AEs in our study were infections (86/235, 36.6%), namely COVID-19
16 (including COVID-19 with hospitalization 60/235, 25.5%) urinary (10/235, 4.3%) and non SARS-CoV-2
17 respiratory tract (9/235, 3.8%) infections. Thirty RMS patients with bacterial infection or COVID-19
18 needed to be treated with antibiotics or sotrovimab and 9/235 (3.8%) patients with COVID-19 need
19 hospitalization (table 1).

20 Two patients developed agranulocytosis (Late-onset neutropenia, defined by low absolute neutrophil
21 count < 500 cells per microliter (μl)), occurring approximately 3-4 weeks after the DMT application
22 [26]). The cause of neutropenia was defined as AEs in the frame of OCR therapy because other
23 etiology, such as bone marrow pathology, infection or autoimmune component, were excluded. None
24 of these two patients experienced fatale outcomes. MS disease remains also stable. After the
25 management of neutropenia, both patients voluntarily discontinued OCR therapy.

26 In our data, none of the patients presented severe (grade III or IV) lymphocytopenia. The mean
27 lymphocyte count during the OCR therapy was 1.9 (95%CI (1.7-2.6), n = 228).

28 Before starting treatment with ocrelizumab, 4/208 (0.02%) of the patients had hypogammaglobulinemia.
29 All patients had primary hypogammaglobulinemia. Serologically examined IgG level 24 months after
30 OCR initiation was in mean 8.2 (95%CI (7.8-8.5), n = 208). In total 36 patients of our study presented
31 with hypogammaglobulinemia defined by IgG < 6.0 g/l (17). Severe infections (with hospitalization and/or
32 treatment) occurred in nearly have of the patients with IgG < 6.0 g/l, which was significantly more
33 frequent compared to those without reduced IgG serum concentration (17/36 (47.2%) vs. 13/172 (7.6%),
34 p<0.001). In 189 patients, we had IgG levels at baseline and during therapy with OCR. Throughout the
35 OCR treatment, 79.4% (150/189) of the RMS patients showed an IgG decrease. In all patients with IgG-
36 follow up, mean IgG-change was -0.40 g/l per years (95%CI, -0.47- -0.34, range -1.9 - 1.0, n=189).

1 Six patients became pregnant during treatment with OCR. Mean time between last infusion and positive
2 pregnancy test was 4.7 months (95%CI (1.6-7.8), n=6). In two pregnancies, this time span was shorter
3 than 3 months. All pregnancies were free of complications, 2 children were delivered by caesarian
4 section (1 elective caesarian section, 1 caesarian section for breech presentation and fetal macrosomia)
5 and no child had other complications.

6

7 **Discussion**

8 In 2018, OCR was introduced for patients with RMS. However, real-world data on the post-marketing
9 use of OCR are still limited. Our study provides real-world data of two Swiss MS centers. The main
10 findings are: 1) In line with the results of RCT and previously published real-world data, it showed
11 efficacy in patients with RMS. 2) Tolerability of OCR was in general good, however infections, IgG
12 decline and the association between both seen in our cohort highlight the need for pharmacovigilance
13 and management strategies for MS patients treated with OCR.

14

15 The population characteristics of real-world data often differ from RCTs. Indeed our RMS cohort has a
16 higher disease duration and percentage of pretreated patients compared to the OPERA population [5].

17

18 Compared with most Real World Data studies (RWDS), our RMS cohort was comparable in terms of
19 age (mean our study: 40.6 vs. range (mean age in years) RWDS 36.3-43.9), disease duration (mean
20 our study: 9.3 vs. range (mean disease duration in years) RWDS 7.7-10.8), and EDSS (mean 2.3 vs.
21 range (mean EDSS) RWDS 2.5-2.9) [8, 11-14, 16, 17]. However, the proportion of pretreated RRMS
22 patients was higher in our study than in most RWDS (mean 68.1% vs. range RWDS 7.8-20%) [8, 12-
23 14, 16, 17].

24

25 In line with the pivotal study and other RWDS, our study confirmed the efficacy of OCR in patients with
26 RMS. The OPERA trials were mainly associated with a low rate of disability progression at 12 and 24
27 weeks of the follow-up. The percentage of patients who met NEDA-3 status was comparable to other
28 RWDS [11, 15, 16], although few RWDS have reported using NEDA-3 status.

29 About three-quarters of RMS patients in the OPERA trial were treatment-naïve, and the most common
30 previous therapies were interferon and glatiramer acetate [5]. In contrast, in our cohort and other
31 observational studies [11, 15], most RMS patients were previously treated, with most patients receiving
32 highly active DMTs, and disease activity was the reason for switching in about one quarter of patients.

33 The most frequent AEs in our study were infections, taking place in 86/235 (36.6%) RMS patients
34 (table 1). COVID-19 was the most common one, followed by urinary infections and other respiratory
35 infections (table 1). All of our patients recovered from the infections, thirty RMS patients (12.8%)
36 received antibiotic therapy. Regarding different real-world data and RCTs, the same predominance of
37 urinary and respiratory infections was observed [11-14, 16, 18].

1 Decreasing serum immunoglobulin levels with an elevated risk for infections due to therapeutic CD 20
2 B-cell depletion were demonstrated previously for OCR [27] and rituximab [28] but not for ofatumumab
3 [29]. In our study, we also detected hypogammaglobulinemia (defined by IgG < 6.0g/l, 36/208 (17.3%))
4 and severe infections (with hospitalization and/or treatment) were more frequent in the patients with IgG
5 < 6.0 g/l compared to those with IgG serum levels \geq 6.0 g/l.

6 Within the OPERA studies, an IgG decrease during OCR treatment was noticed [27]. The annualized
7 IgG decrease in our cohort was slightly higher than the one identified in the RCTs (-0.40 g/L vs -0.32
8 g/L), which could be explained by differences in age as well as pretreatment (table 2). [1]. Especially
9 immunosenescence in the elderly should be investigated in the future, because focusing on those
10 patients with an age > 55 years, not included in the pivotal trials, an even 1.5-fold increased
11 decreased annualized IgG serum concentration was present (-0.65 g/L (95%CI -0.84-(-0.46)), range -
12 1.9-0.17 n=32)). Pharmacovigilance strategies focusing on infections as well as IgG serum
13 concentration are especially important as we have demonstrated clinical relevance of this laboratory
14 finding predisposing for infectious adverse events in our cohort.

15 However, the effect of hypogammaglobulinemia might not be limited to that. A recent retrospective
16 study by our group showed a possible association between hypogammaglobulinemia and fatigue [30].
17 In this regard, an ongoing prospective observational trial (NCT05357781) to investigate whether or not
18 the association between IgG serum level and fatigue is mediated via infections irrespectively of MS
19 immunotherapy is on the way.

20 When interpreting our data, the limitations of a retrospective study with heterogeneous and different
21 follow-up times resulting from different time points of treatment switch must be considered. Here
22 especially the heterogeneity of real world data in comparison to homogenous data from randomized
23 controlled trials has to be taken into account.


24 Concluding our study confirms the efficacy and safety profile of OCR and highlights the need for
25 monitoring and pharmacovigilance strategies to tailor a safe treatment with OCR to the individual risk
26 profile of each MS patient.

27

28

29

30



1
2
3
4
5
6
7

Figure 1: Total number of patients in our cohort.

Abbreviations: RMS: relapsing MS

	RMS (n=235)
Patients characteristics	
Age years, mean (95%CI), n	40.6 (38.8-41.9), 235
Female sex, n (%)	157/235 (66.8)
Time since diagnosis, years, mean (95%CI), n	9.3 (8.40-10.2), 235
EDSS at the beginning of OCR-therapy median (\pm IQR), n	2.0 (\pm 1.5), 235
Duration of the OCR-therapy, years, mean (95%CI), n	2.9 (2.8-3.1), 235
DMT	
No previous DMT, n (%)	75/235 (31.9)

Previously treated with any DMT, n (%)	160/235 (68.1)
mild/ moderate therapies, n (%)	65/235 (27.7)
Interferon beta-1b, n (%)	5/65 (7.7)
Interferon beta-1a, n (%)	8/65 (12.3)
Glatirameracetat, n (%)	12/65 (18.4)
Teriflunomid, n (%)	7/65 (10.7)
Dimethyl Fumarate, n (%)	33/65 (50.7)
(highly-) active therapies, n (%)	95/235 (40.4)
Fingolimod , n (%)	49/95 (51.7)
Natalizumab, n (%)	35/95 (36.8)
Rituximab, n (%)	7/95 (7.3)
Other*, n (%)	4/95 (4.2)
Reason for stopping the previous immunotherapy	
JCV AI positivity in natalizumab treated patients, n (%)	22/160 (13.7)
AEs, n (%)	61/160 (38.1)
Disease activity, n (%)	70/160 (43.8)
Pregnancy, n (%)	5/160 (3.1)
Unknown, n (%)	2/160 (1.3)
Disease activity 12 months before OCR start in all patients	
EDSS	
EDSS, median (\pm IQR), n	2.0 (\pm 2.0), 235
Relapse	
Patient with relapse, n (%)	113/235 (48.1)
Radiological activity	
Patients with MRI activity, n (%)	97/213 (45.5)

New cerebral T1 GELs and/or new cerebral T2 lesions, n (%)	85/97 (87.6)
New spinal T1 GELs and/or new spinal T2 lesions, n (%)	12/97 (12.4)
Disease activity 12 months before OCR start in naïve patients	
EDSS	
EDSS, median (\pm IQR), n	2.0 (\pm 1.5), 75
Relapse	
Patient with relapse, n (%)	47/75 (62.7)
Radiological activity	
Patients with MRI activity, n (%)	41/65 (63.1)
New cerebral T1 GELs and/or new cerebral T2 lesions, n (%)	40/41 (97.6)
New spinal T1 GELs and/or new spinal T2 lesions, n (%)	1/41 (2.4)
Disease activity 12 months before OCR start in patients receiving any previous immunotherapy	
EDSS	
EDSS, median (\pm IQR), n	2.0 (\pm 1.6), 160
Relapse	
Patient with relapse, n (%)	66/160 (41.3)
Radiological activity	
Patients with MRI activity, n (%)	56/148 (37.8)
New cerebral T1 GELs and/or new cerebral T2 lesions, n (%)	46/56 (82.1)
New spinal T1 GELs and/or new spinal T2 lesions, n (%)	10/56 (17.9)
Disease activity during OCR treatment	
NEDA-3 at 12 months	

NEDA-3, n (%)	152/190 (80.0)
EDA, n (%)	38/190 (20.0)
Only radiological activity, n (%)	19/38 (50.0)
Only relapse, n (%)	4/38 (10.5)
Only EDSS progression*, n (%)	11/38 (28.9)
Radiological activity & relapse, n (%)	0/38 (0.0)
Radiological activity & EDSS progression**, n (%)	2/38 (5.3)
Relapse & EDSS progression**, n (%)	1/38 (2.6)
All three criteria (radiological activity, relapse & EDSS progression), n (%)	1/38 (2.6)
NEDA-3 at 24 months	
NEDA-3, n (%)	88/104 (84.6)
EDA, n (%)	16/104 (15.4)
Only radiological activity, n (%)	3/16 (18.8)
Only relapse, n (%)	1/16 (6.3)
Only EDSS progression**, n (%)	9/16 (56.3)
Radiological activity & relapse, n (%)	3/16 (18.8)
Radiological activity & EDSS progression**, n (%)	0/16 (0.0)
Relapse & EDSS progression**, n (%)	0/16 (0.0)
All three criteria (radiological activity, relapse and EDSS progression), n (%)	0/16 (0.0)
Safety	
Infections, n (%)	86/235 (36.6)
Urinary tract infections, n (%)	10/78 (12.8)
Respiratory tract infections, n (%)	9/78 (11.5)
Gastrointestinal tract infections, n (%)	1/78 /1.3)

COVID-19 without hospitalization, n (%)	51/78 (65.4)
COVID-19 with hospitalization, n (%)	9/78 (11.5)
Other infections, n (%)	6/78 (7.7)
Treatment of any infections with antibiotics or Sotrovimab, n (%)	30/235 (13.2)
Severe infections (infection with hospitalization and/or treatment, n (%)	31/235 (13.2)
Increased transaminases***, n (%)	4/235 (1.7)
Lymphopenia**** CTCAE grade II, n (%)	2/235 (0.4)
Agranulocytosis*****, n (%)	2/235 (0.8)
Hypogammaglobulinemia*****, n (%)	36/208 (17.3)
Cytokine release syndrome during OCR infusion (CTCAE Grad III, n (%)	1/235 (0.4)
Lymphocyte (G/l) value during OCR, mean (95CI%), n	1.9 (1.7-2.6), 228
IgG value (g/l) during OCR, mean (95CI%), n	8.2 (7.8-8.5), 208
IgG decrease compared to baseline, n (%)	161/184 (87.5)
Annualized IgG change (g/l), mean (95CI%), n	-0.40 (0.47-(-0.34)), 189
Annualized IgG change (g/l) in patients ≤ 55 years, mean (95CI%), n	-0.35 (-0.41- (-0.28)), 156
Annualized IgG change (g/l) in patients > 55 years, mean (95CI%), n	-0.65 (-0.84- (-0.36)),32
Severe infections in patients with IgG < 6g/l, n (%)	17/36 (42.7)
Severe infections in patients with IgG > 6g/l, n (%)	13/172 (7.6)
Pregnancy during OCR therapy, n (%)	6/234 (2.6)
Time between last OCR infusion and positive pregnancy test, months, mean (95%CI), n	4.7 (1.6-7.8), 6

Pregnancy/Delivery complication, n (%)	0/6 (0.0)
--	-----------

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21

Table 1: Characteristics of patients under OCR in two groups (RMS vs. PPMS)

Abbreviations: AE: adverse events; cMRI: cerebral Magnetic Resonance Tomography; CTCAE: Common Terminology Criteria for Adverse Events; DMT: Disease-modifying therapy; EDA: evidence of disease activity; EDSS: The Expanded Disability Status Scale; GELs: Gadolinium-enhanced Lesions; IQR: Interquartile range; JCV AI: John Cunningham Virus Antibody Index; n: number of observations; NEDA-3: no evidence of disease activity-3; OCR: Ocrelizumab; RMS: relapsing MS; 95%CI: 95% Confidence interval.

Other*: mitoxantrone, daclizumab

EDSS progression**: elevation of the EDSS Score of 1 point from the baseline EDSS was 0 to 5.5 and 0.5 points if the baseline EDSS score was 6.0 or more compared to the last clinical assessment.

Increased transaminases***: Aspartate transaminase > 35 U/l and/or Alanine transaminase > 45 U/l

Lymphopenia****: CTCAE Grade 0/ normal: ≥ 1 /G/l, Grade I: 0.80-0.99 G/l, Grade II: 0.50 – 0.79 G/l, Grade III: 0.20-0.49 G/l, Grade IV: <0.20 G/l.

Agranulocytosis*****: Neutrophils < 500 cells per microliter (μ l) corresponding to CTCAE Grade IV

Hypogammaglobulinemia*****: IgG serum level < 6.0 g/l with or without infection (Infections CTCAE: CTCAE grade 2 requiring oral antibiotic intervention; CTCAE grade 3 and grade 4 requiring hospitalization, and/or intravenous antibiotics).

Baseline characteristics	Diem et al. (n=235)	OPERA OCR arm (n=410)	OPERA Interferon arm (n=411)
Age (years), mean, SD	40.4 (12.1)	37.1 (9.3)	36.9 (9.3)
Female, n (%)	157 (67)	270 (66)	272 (66)
Duration of the disease, y, mean, SD	9.3 \pm 9.0	3.8 \pm 4.8	3.7 \pm 4.6
EDSS before OCR, median, SD	2.3 \pm 1.6	2.9 \pm 1.2	2.8 \pm 1.3

Naïve, n (%)	75 (32)	301 (74)	292 (71)
Previously treated patients, n (%)	160 (68)	107 (26)	117 (29)

1
2
3
4
5
6

Table 2: Comparison of baseline characteristics of Diem et al and the OPERA I. trial [5]

Abbreviations: EDSS: Expanded Disability Status Scale; OCR: Ocrelizumab; RMS: relapsing MS; n: number of observations; SD: standard deviation; y: years.

	Before start OCR-therapy	12 months after OCR-therapy start	p-value
Median EDSS (±IQR), n	2.0 (±2.0), 190	2.0 (±2.0), 190	0.043
Patients with relapse, n (%)	60/190 (31.6)	5/190 (2.6)	<0.001
Mean ARR, (95CI%), n	0.4 (0.3-0.4), 190	0.03 (0.003-0.05), 190	<0.001
Radiological activity, n (%)	88/190 (46.3)	22/190 (11.6)	<0.001
	Before start OCR-therapy	24 months after OCR-therapy start	p-value
Median EDSS (±IQR), n	2.0 (±2.0), 104	2.5 (±1.5), 104	0.003
Patients with relapse, n (%)	42/104 (40.4)	4/104 (3.8)	<0.001
Mean ARR, (95CI%), n	0.2 (0.2-0.4), 104	0.04 (0.001-0.08), 104	<0.001
Radiological activity, n (%)	38/104 (36.5)	5/104 (4.8)	<0.001

7
8

Table 3: Comparison disease activity before and 12/24 months after OCR start in RMS patients.

Abbreviations: ARR: Annualized relapse rate; EDSS: Expanded Disability Status Scale; IQR: Interquartile range; OCR: Ocrelizumab; 95%CI: 95% Confidence interval.

Statistics: Quantitative variables are described using the mean and 95% confidence interval (95%CI) and compared with Wilcoxon Test. Qualitative variables are presented as absolute and relative

1 frequencies and were compared with Mc-Nemar-Test. Adjustment for multiple testing was performed by
2 Bonferroni procedure in regard to each domain independently: p-value= 0.0125

3

4

5

6

7

8

9

Study reference	Study design	Year	N. of subjects in study	Population/Baseline for total population	Main findig
V. Prockl et al. doi : https://doi.org/10.1016/j.jns.2020.116973	Monocentric, retrospective cohort study	2019	Total: 128 Female: 81	86 RMS patients, 42 PPMS patients Age in years, mean (range) 41.0 (18.0–76.0) EDSS, mean (IQR) 3.5 (2.0–5.0) Disease duration in months mean (IQR): 75.0 (37.0–172.0)	<i>Efficiency:</i> Low count of the relapses during the observational period. <i>Safety:</i> no severe adverse events occurred during the observational time.
H. Coban et al. doi : https://doi.org/10.1016/j.msard.2021.103021	Monocentric retrospective observational trial	2017-2020	Total: 82 Female: 42	59 RMS patients, 14 PPMS patients, 9 SPMS patients Age in years, mean (\pm SD): RMS 38 (\pm 11), PPMS 46 (\pm 10), 48 (\pm 11) SPMS, EDSS, mean (\pm SD) RMS 2.2 (\pm 1.0), PPMS 4.6 (\pm 1.5), SPMS 5.8 (\pm 2.7)	<i>Efficiency:</i> the study sustains a general efficiency and tolerability of the OCR: Annualized relapse rate under OCR by RMS was reduced from 1.33 to 0.15. The EDSS did not get worse during the OCR treatment in all subpopulations and different ethnic groups. Number of new or enlarging T2 lesion 10 (5) by RMS and 10 (5) by PPMS.

<p>K. Daniels et al. doi :https://doi.org/10.1155/2020/5463451</p>	<p>Monocentric retrospective cohort study</p>	<p>2018</p>	<p>Total: 21 Female: 14</p>	<p>PPMS patients Age in years, mean (\pmSD) 52.09 (\pm6.42) EDSS, mean (\pmSD) 5.33 (\pm1.13)</p>	<p><i>Efficiency:</i> effectiveness of OCR was sustained by stabilizing the clinical progression rate: Disability progression in “pre-treatment” time higher than this rate while on treatment, showing that the disability progression rate per 12 weeks was significantly decreased after the first ocrelizumab dose application than before treatment began.</p>
<p>E. Fernandez-Diaz et al. doi: 10.1002/acn3.51282</p>	<p>multicenter, retrospective, observational study</p>	<p>2020</p>	<p>Total: 228 Female: 124</p>	<p>144 RMS patients, 59 PPMS patients Age in years, mean (\pmSD) 39 (\pm5.9)</p>	<p><i>Efficiency:</i> Clinical and radiological effectiveness: 13 (7.7%) RMS patients had a relapse after treatment initiation, 7/102 (6.9%) RMS patients had MRI activity at 12 months after ocrelizumab; 18 (37.5%) PPMS patients experienced disability progression</p> <p><i>Safety:</i> 2 patients of the whole population developed severe AEs. None of the 4 patients with a prior history of tumor showed the new appearance of the neoplasm. The COVID-rate was 1.3 % among the population.</p>

<p>E. Ellwardt et al. doi:10.1212/NXI.00000000000000719</p>	<p>Monocentric retrospective cohort study</p>	<p>2019</p>	<p>Total: 210 Female: 125</p>	<p>155 RMS patients, 55 PPMS patients Age in years, mean (\pmSD) 39.2 (\pm10.7) EDSS, mean (\pmSD) 3.6 (\pm1.9)</p>	<p><i>Efficiency:</i> sustained effectiveness: 21 patients (15%, 95% CI 0.093–0.216) showed a clinical activity: 14 relapses (10%) in RRMS population, 7 PPMS-patients with progression 5% after OCR start.</p> <p><i>Safety:</i> Only 22% (46 patients of 210) of the patients presented with side effects, no severe adverse events were reported.</p>
<p>Pontieri L. et al. doi:10.1111/ene.15142</p>	<p>nationwide population-based/multicentric cohort study</p>	<p>2018-2020</p>	<p>Total: 1104 Female: 695</p>	<p>85.7% RMS patients, 8.8% SPMS patients, 5.5% PPMS patients. Age in years, mean: 41.4 years RRMS, 44.5 PPMS and 50.3 SPMS EDSS, mean: 2.5, 3.5 and 5.5, respectively.</p>	<p><i>Efficiency:</i> after ocrelizumab start 9.3% of the RRMS-patients presented a clinical relapse, 8.7% of PPMS population at 24 week showed disability progression, while 16.7% of the patients showed at 24. week disability improvement. One year after the begin of treatment, 94.5% of the patients were without any radiological activity.</p> <p><i>Safety:</i> Side effects were only reported for 10% of patients, no severe adverse events.</p>
<p>Buttmann et al. doi:10.3389/fneur.2022.863105</p>	<p>CONFIDENCE (ML39632, EUPAS22951) is an ongoing multicenter, non-interventional post authorization safety study</p>	<p>2018-ongoing</p>	<p>Total: 2100 Female: 1139</p>	<p>1702 RMS patients, 398 PMS patients Age in years, mean (\pmSD): RMS 41.6 (\pm11.2). PPMS 50.9 (\pm9.9) EDSS mean (\pmSD): RMS 3.18 (\pm1.87), PPMS 4.41 (\pm1.59)</p>	<p><i>Safety:</i> 721 (42.4%) patients with RMS and 147 (36.9%) PPMS patients with PPMS presented adverse events; 7 patients with RMS were diagnosed with new malignancies</p>

<p>M Cellerino et al. doi.org/10.1007/s13311-021-01104-8</p>	<p>Monocentric observational prospective cohort study</p>	<p>2019-2021</p>	<p>Total: 153 Female: 84</p>	<p>93 RMS patients, 60 PPMS patients Age in years, mean (\pmSD) 41.9 (\pm11.4) EDSS, median (IQR) 3.5 (2–5.5)</p>	<p><i>Efficiency:</i> 95.1% RMS patients were free of clinical relapses at 2 years Follow-up, 64.7 % of PPMS were free from disease progression at the same time point. 67.1% RMS and 81.3% PPMS did not present any radiological activity at the two years of follow up.</p>
<p>Sempere et al. doi: 10.3389/fneur.2020.592304</p>	<p>Multicentric retrospective observational study</p>	<p>2020</p>	<p>Total: 70 Female:42</p>	<p>30% PPMS; 70% RMS Age in years, mean (\pmSD) RMS 39.2 (\pm10.9), PPMS 47.1 (\pm10.5) EDSS median (IQR): 2.5 (2–3) for RRMS and 3.0 (3–4.8) for PPMS</p>	<p><i>Efficiency:</i> Annualized relapse rate after OCR start in RRMS population was 0.02, disability progression by PPMS 1/70 (1.4%). New T2-hyperintense lesions at 12 months were detected by 1/46 (2.2%)</p> <p><i>Safety:</i> Adverse events 37 (53%), no severe adverse events were sustained.</p>
<p>Braune S et al. https://www.neurotransdata.com/images/publikationen/2020-braune_real-world.pdf</p>	<p>Secondary data analysis of patients enrolled in the German NTD Registry</p>	<p>2020</p>	<p>Total: 395 Female: 271</p>	<p>35 PPMS; 352 RRMS; 35 rSPMS Age in years, mean (Q1-Q3) RMS 41.7 (33.7, 51.8), PPMS 52.5 (47.1, 57.3), rSPMS 54.4 (48.6, 59.7) EDSS median (Q1-Q3): 2.5 (1.5, 4.0) for RRMS, 4 (3.0, 5.9) for PPMS, 6 (5.0, 7.0) for rSPMS</p>	<p><i>Efficiency:</i> Annualized relapse rate, per PY (95% CI): 0.13 (0.09, 0.16)</p>

<p>Smoot K et al.</p> <p>https://digitalcommons.psjhealth.org/publications/1403/</p>	<p>Providence OCR Registry</p>	<p>2019</p>	<p>Total: 309 Female: 224</p>	<p>76.3% RMS, 14.3%SPMS, 9.4% PPMS Age in years, mean (SD) 51.9 (12.0) EDSS median (IQR): RRMS 3.0 (2.0, 4.0), SPMS 6.5 (6.0, 7.5), PPMS 6.5 (5.8, 7.1)</p>	<p><i>Efficiency:</i> ARR was 0.10 with two patients having two relapses. Median EDSS scores at 12 months were 3.0 [2.0, 5.0] (n=98) for RMS patients, 6.5 [5.5, 7.5] (n=23) for SPMS, and 6.5 [5.0, 7.5] (n=13) for PPMS.</p> <p><i>Safety:</i> Infusion reactions occurred in 33.6% of patients during dose one, becoming less frequent with subsequent doses (15.1%). Respiratory infections occurred in 32.1% of patients followed by urinary tract infections (UTI) (25.3%). Of the 22 hospitalizations that have occurred, 9 were due to infection, majority due to UTIs (89.9%) with four patients developing sepsis.</p>
--	--------------------------------	-------------	-----------------------------------	---	--

Supplementary Table 1: List of Ocrelizumab real-world study

Abbreviations: 95% CI: 95% confidence interval; COVID: Corona-Virus Disease; EDSS: Expanded Disability Status Scale; IQR: Interquartile range; OCR: ocrelizumab; PPMS: primary progressive multiple sclerosis; RMS: relapsing multiple sclerosis; SD: standard deviation; SPMS: Secondary progressive multiple sclerosis

1 st line therapies	glatiramer acetate, interferon teriflunomide dimethyl fumarate fingolimod
2 nd line therapies	natalizumab rituximab others: mitoxantrone, daclizumab

Supplementary table 2: Definition of 1st and 2nd line therapies

Reference:

1. Gelfand, J.M., B.A.C. Cree, and S.L. Hauser, *Ocrelizumab and Other CD20(+) B-Cell-Depleting Therapies in Multiple Sclerosis*. Neurotherapeutics, 2017. **14**(4): p. 835-841.
2. Pharmacology, A.C.o.C., *FDA Approves OCREVUS (Ocrelizumab) for Treatment of Adult Patients with Relapsing or Primary Progressive Forms of Multiple Sclerosis*. 2017:
https://accp1.org/Members/ACCP1/5Publications_News/FDA_Approves_OCREVUS_Ocrelizumab.aspx.
3. Swissmedic, *OCREVUS® (Ocrelizumab)*

*Konzentrat zur Herstellung einer Infusionslösung,
300mg/10ml*

Zul.-Nr. 66185, R.P.S. AG, Editor. 2018.

4. (EMA), E.M.A., *Ocrelizumab*. 2018.
5. Hauser, S.L., et al., *Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis*. N Engl J Med, 2017. **376**(3): p. 221-234.
6. Montalban, X., et al., *Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis*. N Engl J Med, 2017. **376**(3): p. 209-220.
7. Hauser, S.L., et al., *Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension*. Neurology, 2020. **95**(13): p. e1854-e1867.
8. Prockl, V., et al., *Real world application of ocrelizumab in multiple sclerosis: Single-center experience of 128 patients*. J Neurol Sci, 2020. **415**: p. 116973.
9. Coban, H., et al., *Real-world experience of ocrelizumab initiation in a diverse multiple sclerosis population*. Mult Scler Relat Disord, 2021. **53**: p. 103021.

10. Daniels, K., et al., *Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis*. *Mult Scler Int*, 2020. **2020**: p. 5463451.
11. Fernandez-Diaz, E., et al., *Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population*. *Ann Clin Transl Neurol*, 2021. **8**(2): p. 385-394.
12. Ellwardt, E., et al., *Ocrelizumab initiation in patients with MS: A multicenter observational study*. *Neurol Neuroimmunol Neuroinflamm*, 2020. **7**(4).
13. Pontieri, L., et al., *Ocrelizumab treatment in multiple sclerosis: A Danish population-based cohort study*. *Eur J Neurol*, 2022. **29**(2): p. 496-504.
14. Buttmann, M., *Assessing the real-world effectiveness of ocrelizumab in patients with multiple sclerosis-confidence one-year interim analysis [abstract]*. *Mult Scler J*, 2020.
15. Cellerino, M., et al., *Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis*. *Neurotherapeutics*, 2021. **18**(4): p. 2579-2588.
16. Sempere, A.P., et al., *Ocrelizumab in Multiple Sclerosis: A Real-World Study From Spain*. *Front Neurol*, 2020. **11**: p. 592304.
17. Braune, S., *Real-world experience with ocrelizumab in the German neurotransdata registry*. *Mult Scler J.*, 2020.
18. al., S.K.e., *Utilization, safety, and tolerability of ocrelizumab: year 2 data from the Providence Ocrelizumab Registry*. 2019.
19. Thompson, A.J., et al., *Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria*. *Lancet Neurol*, 2018. **17**(2): p. 162-173.
20. Thompson, A.J., et al., *Multiple sclerosis*. *Lancet*, 2018. **391**(10130): p. 1622-1636.
21. Kalincik, T., et al., *Defining reliable disability outcomes in multiple sclerosis*. *Brain*, 2015. **138**(Pt 11): p. 3287-98.
22. Pandit, L., *No Evidence of Disease Activity (NEDA) in Multiple Sclerosis - Shifting the Goal Posts*. *Ann Indian Acad Neurol*, 2019. **22**(3): p. 261-263.
23. *MSD Manual: Normal Laboratory Values*. Available from: <https://www.msdmanuals.com/professional/resources/normal-laboratory-values/normal-laboratory-values>.
24. *Common Terminology Criteria for Adverse Events (CTCAE)*. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm.
25. Ovchinnikov, A. and O. Findling, *An overview of pivotal trials and real-world evidence for CD20-depleting therapy in multiple sclerosis : Immunotherapy with rituximab, ocrelizumab, and ofatumumab*. *Wien Med Wochenschr*, 2022. **172**(15-16): p. 359-364.
26. Wolach, O., O. Bairey, and M. Lahav, *Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature*. *Medicine (Baltimore)*, 2010. **89**(5): p. 308-318.
27. Hauser, S.L., et al., *Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis*. *Neurology*, 2021. **97**(16): p. e1546-e1559.
28. Barmettler, S., et al., *Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia*. *JAMA Netw Open*, 2018. **1**(7): p. e184169.
29. Hauser, S.L., et al., *Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years*. *Mult Scler*, 2022. **28**(10): p. 1576-1590.
30. Diem, L., et al., *Hypogammaglobulinemia: A contributing factor to multiple sclerosis fatigue?* *Mult Scler Relat Disord*, 2022. **68**: p. 104148.